Erroneous Payment Corrections for NovoEight Products

May 13, 2021

Effective retroactively for dates of service on or after October 1, 2020, and January 1, 2021, Novo Nordisk restated prices that may affect reimbursement for NovoEight products for the fourth quarter of 2020 and the first quarter of 2021.

These reimbursements will be automatically adjusted to reflect the accurate values restated. An Erroneous Payment Correction (EPC) will be implemented to reprocess the affected claims.